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Context: The classic androgen synthesis pathway proceeds via DHEA, androstenedione and testosterone 38	
to 5a-dihydrotestosterone (DHT). However, DHT synthesis can also be achieved by an alternative pathway 39	
originating from 17α-hydroxyprogesterone (17OHP), which accumulates in congenital adrenal hyperplasia 40	
(CAH). Similarly, recent work has highlighted androstenedione-derived 11-oxygenated 19-carbon steroids 41	
as active androgens and, in CAH, androstenedione is generated directly from 17OHP. The exact 42	
contribution of alternative pathway activity to androgen excess in CAH and its response to glucocorticoid 43	
therapy is unknown.  44	
Objective: We sought to quantify classic and alternative pathway-mediated androgen synthesis in CAH, 45	
their diurnal variation and their response to conventional glucocorticoid (GC) therapy and modified release 46	
hydrocortisone. 47	
Methods: We employed urinary steroid metabolome profiling by gas chromatography-mass spectrometry 48	
for 24-h steroid excretion analysis, studying the impact of conventional GCs (hydrocortisone, prednisolone, 49	
dexamethasone) in 55 adults with CAH and 60 controls. We studied diurnal variation in steroid excreton 50	
by comparing 8-hourly collections (23:00-7:00h, 7:00-15:00h, 15:00-23:00h) in 16 CAH patients on 51	
conventional glucocorticoids and during six months of treatment with modified release hydrocortisone, 52	
Chronocort. 53	
Results: CAH patients on conventional GCs showed low excretion of classic pathway androgen metabolites 54	
but excess excretion of the alternative pathway signature metabolites 3α,5α-17-hydroxypregnanolone and 55	
11b-hydroxyandrosterone. Chronocort reduced 17OHP and alternative pathway metabolite excretion to 56	
near normal levels more consistently than other GC preparations.  57	
Conclusions: Alternative pathway mediated androgen synthesis significantly contributes to androgen 58	
excess in CAH.  Chronocort therapy appears superior to conventional GC therapy in controlling androgen 59	





Disruption of glucocorticoid (GC) synthesis is the defining feature of all variants of congenital 63	
adrenal hyperplasia (CAH) including its most prevalent cause, 21-hydroxylase deficiency (21OHD) (1). 64	
This enzymatic block results in GC deficiency, with the consequent loss of negative feedback to the 65	
pituitary gland and hypothalamus, driving both ACTH-mediated adrenal androgen excess and adrenal 66	
hyperplasia. Mineralocorticoid deficiency may also be seen in 21OHD, but to a variable degree dependent 67	
on mutation severity (2).  68	
The classic pathway of androgen synthesis proceeds through dehydroepiandrosterone (DHEA), 69	
androstenedione and testosterone to the most potent activator of the androgen receptor, 5α-70	
dihydrotestosterone (DHT). The substrate of 21-hydroxylase, 17α-hydroxyprogesterone (17OHP), 71	
accumulates in CAH due to 21OHD, resulting in enhanced conversion to androstenedione and active 72	
androgens. However, 17OHP is also a substrate for an alternative pathway to androgen biosynthesis, which 73	
generates DHT without the need for DHEA, androstenedione or testosterone as intermediates (3, 4). In this 74	
pathway, 17OHP is converted by consecutive 5α-reductase and 3α-HSD activity to 3α,5α-17-75	
hydroxypregnanolone (3α,5α-17HP) and then downstream to DHT (Fig. 1) (5). Accumulation of the 76	
alternative pathway intermediate 3α,5α-17HP has been demonstrated in untreated patients with CAH due 77	
to 21OHD (6), but its relative contribution to excess androgen synthesis has not yet been investigated. 78	
Furthermore, recent work has highlighted the role of another androgen biosynthesis pathway that converts 79	
androstenedione in several steps to 11-keto-testosterone and 11-keto-dihydrotestosterone (Fig. 1), steroids 80	
that have been shown to act as potent androgen receptor agonists (7-11). 81	
Conventional management strategies for CAH include the use of both immediate release 82	
hydrocortisone and longer-acting synthetic GC preparations, sometimes prescribed in a reverse circadian 83	
pattern (1). These preparations fail to mimic the normal diurnal profile of cortisol secretion and therefore 84	
do not prevent the early morning surge of ACTH that is the major driver of adrenal-mediated androgen 85	
excess in CAH. As a consequence, the current management of patients with CAH is complicated by the 86	
need to strike a balance between sufficient control of endogenous androgen excess and potential excess 87	
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exposure to exogenous GCs (12). A modified and delayed release GC preparation, Chronocort, has recently 88	
been developed and shown to approximate the physiological diurnal rhythm of cortisol release due to 89	
delayed release, with peak levels during the early morning hours after intake at bedtime (13, 14). The 90	
relative impact of both conventional GC preparations and Chronocort on androgen synthesis by classic and 91	
alternative pathways is not known.  92	
In this study, we sought to quantify the diurnal contribution of alternative pathway androgen 93	
synthesis to androgen excess in CAH by assessing the excreted urinary steroid metabolome of 21OHD 94	
patients. We investigated patients receiving conventional GC therapy and patients treated with the modified 95	
release hydrocortisone preparation Chronocort in comparison to healthy controls with intact diurnal 96	
secretion of cortisol.  97	
SUBJECTS AND METHODS 98	
Subjects 99	
Alternative pathway androgen synthesis in subjects with CAH managed with conventional GC 100	
therapy was quantified by analysis of 24-hour urinary steroid metabolite excretion in 55 adult subjects with 101	
21OHD, recruited from two specialist centers, Birmingham and Munich, and 60 sex- and age-matched 102	
controls, recruited from Birmingham. In all participating patients, the diagnosis of 21-hydroxylase 103	
deficiency had previously been confirmed following genetic testing as part of their routine clinical care. 104	
Control subjects were healthy individuals without chronic disease aged 18-80 years. None were taking oral 105	
contraceptives, hormone replacement therapy other than corticosteroid replacement or other medications 106	
known to alter steroid hormone synthesis and/or metabolism at the time of urine collection.  107	
A summary of patient and control characteristics is provided in Table 1. The majority of the 21OHD group 108	
were managed with prednisolone (n=27; 49%; median daily dose 7.5 mg, range 5-15 mg) and the remainder 109	
with either hydrocortisone (n=13; 24%; median daily dose 30 mg, range 20-37.5 mg) or dexamethasone 110	
(n=15; 27%; median daily dose 0.5 mg, range 0.25-1.00 mg). All patients with salt-wasting CAH and some 111	
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with simple-virilizing CAH received additional mineralocorticoid replacement; daily fludrocortisone doses 112	
ranged between 100-300 µg. 113	
The impact of the modified release hydrocortisone preparation Chronocort on alternative pathway 114	
synthesis was assessed in a subgroup consisting of 16 subjects with 21OHD. All were enrolled in an open-115	
label phase 2 study at the National Institutes of Health Clinical Centre (clinical trials.gov #NCT01735617) 116	
(14). Subjects were maintained on twice-daily Chronocort therapy for a period of six months with dose 117	
adjustment employed based on clinical symptoms and serum biochemistry. Median daily Chronocort dose 118	
at six months was 27.5 (range 15-40) mg. Urinary steroid metabolite excretion was measured at baseline, 119	
at day four of Chronocort therapy and after six months of treatment. Three eight-hour urine samples were 120	
collected within each of these three 24 hour periods and were timed to reflect either night (23:00-07:00), 121	
morning (07:00-15:00) or evening (15:00-23:00) periods. Steroid excretion in the 8-hourly urine collection 122	
was compared to that of 12 healthy control subjects (median age 32.9 years) who also provided three eight-123	
hour urine collections with similar timing to reflect night, morning or evening periods. All participants 124	
provided informed written consent. Ethical approval for the collection of baseline data was provided by 125	
South Birmingham Research Ethics Committee (REC) for healthy controls, and by West Midlands MREC 126	
and the University Hospital Ethics Committee Munich for conventionally managed CAH patients. Phase 2 127	
study approval for the Chronocort-treated CAH patients was provided by the Eunice Kennedy Shriver 128	
National Institute of Child Health and Human Development Institutional Review Board at the National 129	
Institute of Health, USA. 130	
Urinary steroid hormone analysis 131	
Analysis of urinary excretion of steroid hormone metabolites was undertaken by quantitative gas 132	
chromatography-mass spectrometry (GC-MS) in selected-ion-monitoring analysis mode as described 133	
previously (7). Suppl. Table 1 summarizes the steroid metabolites relevant to this study. 134	
The 21-hydroxylase enzyme, CYP21A2, catalyzes the conversion of 17OHP to the cortisol 135	
precursor 11-deoxycortisol. The metabolic impact of 21OHD was thus assessed through analysis of 136	
tetrahydro-11-deoxycortisol (THS), the metabolite of the CYP21A2 product 11-deoxycortisol, and the 137	
7	
	
17OHP metabolites 17-hydroxypregnanolone (17HP) and pregnanetriol (PT) as well as pregnanetriolone 138	
(PTONE). PTONE is the metabolite of 21-deoxycortisol, which is generated from 17OHP by CYP11B1 139	
and only produced in appreciable amounts in the absence of 21-hydroxylase activity, i.e. in 21OHD.  140	
Classic androgen pathway activity was measured by quantification of the major androgen 141	
metabolites androsterone (An) and etiocholanolone (Et). Activation of the alternative pathway to DHT was 142	
assessed through quantification of its signature metabolite 3α,5α-17HP. While androstenedione and 143	
testosterone both feed into An and Et, the most potent androgen, DHT, is only represented in the 5α-reduced 144	
androgen metabolite An. Thus the Et pool is only enhanced by classic androgen pathway activity while the 145	
An pool increases with DHT synthesis via both the classic and alternative pathways. We therefore used the 146	
ratio 3α5α17HP/An as an estimate of the proportional contribution of the alternative pathway to androgen 147	
synthesis. 148	
19-carbon androgens oxygenated at position C-11 have been shown to be produced by the adrenal 149	
glands and 11-keto-testosterone and 11-keto-DHT have been shown to activate the androgen receptor (7, 150	
10). Therefore, we measured the concentration of the major metabolite of urinary 11-oxy-C19 steroid 151	
metabolites, 11β-hydroxyandrosterone (11β-OH-An).  152	
Statistical analysis 153	
Data are presented as median and interquartile range (IQR) unless otherwise stated. Analyses were 154	
undertaken using the non-parametric Mann-Whitney and Kruskal-Wallis with posthoc Dunn tests for 155	
unpaired analyses. Paired data was analyzed using the non-parametric Wilcoxon test with Bonferroni 156	
correction applied for repeated analyses. Statistical analyses were undertaken using SPSS Statistics 21 157	
(IBM) and p-values <0.05 considered significant. All p-values were two sided.  158	
RESULTS 159	
24-h steroid metabolite excretion in CAH patients receiving conventional glucocorticoid therapy  160	
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As expected, the excretion of the 17OHP metabolites 17HP and PT and the 21-deoxycortisol 161	
metabolite PTONE, were significantly increased in CAH (p<0.001), indicative of impaired 21-hydroxylase 162	
activity. Conversely, the product of 21-hydroxylase activity, the 11-deoxycortisol metabolite THS, was 163	
significantly lower (p<0.001) in subjects with CAH than in control subjects (Fig. 2A+B).  164	
The urinary excretion of the sum of the major androgen metabolites An and Et was significantly 165	
lower in subjects with CAH managed with conventional GC therapy than in sex- and age-matched control 166	
subjects (Fig. 2C; p<0.001). Conversely, the signature metabolite of the alternative pathway to DHT 167	
synthesis, 3α5α-17HP, was significantly increased in subjects with CAH (Fig. 2D; p<0.001). The ratio of 168	
3α,5α-17HP to An was calculated in order to quantify the contribution of the alternative pathway to total 169	
synthesis of 5a-reduced androgens including DHT. This ratio was significantly increased in subjects with 170	
CAH while alternative pathway activity in the controls was negligible (p<0.001) (Fig. 2E). The excretion 171	
of the major metabolite of 11-oxygenated 19-carbon steroids, 11β-OH-An, appeared similar to that in 172	
controls, with broad inter-individual variability in excretion amounts (Fig. 2F).  The pattern of changes 173	
remained similar when carrying out sex-specific sub group analyses (Suppl. Fig. 3), which also revealed 174	
higher excretion of the metabolites of 17OHP (Suppl. Fig. 3A) and classic and alternative pathway 175	
metabolites (Suppl. Fig. 3C,D,F) in male controls as compared to female controls, whereas no significant 176	
difference was observed between male and female CAH patients. 177	
Diurnal variation in steroid excretion in CAH patients receiving conventional glucocorticoid therapy  178	
Diurnal excretion analysis in urines collected in 8-hour intervals reflecting night (23:00-07:00h), 179	
morning (7:00-15:00h) and evening (15:00-23:00h) showed a similar picture to the 24-h urine analysis 180	
when comparing CAH patients (n=16; four of whom were managed with hydrocortisone, seven with 181	
prednisolone and five dexamethasone) to control subjects (n=12), with lower classic pathway but higher 182	
excretion of the signature metabolite of the alternative pathway to DHT in CAH patients (Fig. 3).  183	
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Healthy control subjects showed significant diurnal variability of the metabolites of 17OHP and 184	
the classic and alternative androgen pathways (Fig. 3), with lowest excretion during night time. By contrast, 185	
this diurnal excretion pattern was lost in CAH patients receiving conventional glucocorticoid therapy. 186	
Differential impact of conventional glucocorticoid preparations on steroid excretion 187	
To assess the effect of distinct conventional GC therapies on androgen synthesis, we compared 188	
urinary steroid metabolite excretion in CAH patients managed with hydrocortisone (n=13), prednisolone 189	
(n=27), and dexamethasone (n=15), respectively; all had been on stable treatment for at least six months. 190	
This revealed that hydrocortisone-treated CAH patients had significantly higher excretion of 17OHP 191	
metabolites, the sum of the androgen metabolites An+Et and also the major adrenal androgen metabolite 192	
11β-OH-An in comparison to dexamethasone-treated patients, with prednisolone-treated in an intermediate 193	
position (Suppl. Fig. 1). Similarly, hydrocortisone therapy appeared associated with the highest excretion 194	
of the alternative pathway metabolite 3α,5α-17HP but this difference was not statistically significant due to 195	
high inter-individual variability. 196	
Diurnal steroid excretion during modified release hydrocortisone treatment  197	
We assessed urinary steroid excretion in 16 patients with CAH at baseline, i.e. on conventional GC 198	
treatment, and during treatment with modified release hydrocortisone, with diurnal urine collections in 8-199	
hourly intervals. This was carried out on three occasions: at baseline when still receiving conventional GC 200	
therapy, shortly after initiation of Chronocort treatment, day 4, and after six months of continuous treatment 201	
with Chronocort. 202	
 The analysis of the total 24-h urine excretion revealed a significant reduction in the combined 203	
excretion of the markers of impaired 21-hydroxylase activity, the sum of 17α-hydroxyprogesterone 204	
metabolites 17HP, PT and the 21-deoxycortisol metabolite PTONE, both after four days and six months of 205	
Chronocort treatment (all p<0.05) (Fig. 4), with lower excretion amounts than observed in patients treated 206	
with any other GC preparation (Fig. 5). Total classic pathway androgen metabolite excretion, An+Et, and 207	
excretion of the alternative androgen pathway metabolite 3α5α-17HP significantly decreased after 208	
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Chronocort treatment to lower levels than observed with any other GC preparation (Fig. 4+5). The excretion 209	
of 11β-OH-An also appeared to decrease albeit not significantly (Fig. 4). Attenuation of 11-oxygenated 19-210	
carbon androgen synthesis in Chronocort-treated patients was at least similar to dexamethasone or 211	
prednisolone treatment and superior to the effects of hydrocortisone treatment (Fig. 5). Of note, 24-h 212	
urinary excretion of 11-hydroxy-etiocholanolone and 11-oxo-etiocholanolone, which are exclusive 213	
glucocorticoid metabolites (15) and therefore reflective of the amount of exogenous cortisol, showed a 214	
higher excretion in patients treated with conventional hydrocortisone than in patients on Chronocort. 215	
The effect of six months of Chronocort therapy on the diurnal rhythm of urinary steroid excretion 216	
in subjects with CAH is shown in Suppl. Fig. 2. There was less variability seen across the three 8-hour 217	
periods in the excretion of the metabolites of CYP21A2 following Chronocort than prior to its initiation. 218	
Notably, the early morning surge (night time period, 23:00-7:00h) in the activation of classic and alternative 219	
androgen pathway synthesis appeared diminished following Chronocort therapy (Suppl. Fig. 2C-F). 220	
DISCUSSION 221	
In this study, employing 24-h urinary steroid metabolome profiling, we could show that alternative 222	
pathway androgen synthesis contributes significantly to androgen excess in CAH patients receiving chronic 223	
GC therapy, both via the 11-oxygenated 19-carbon androgen pathway and via DHT synthesis from 17OHP. 224	
In addition, we have identified the differential impact of conventional GC therapies and treatment with 225	
modified release hydrocortisone (Chronocort) on steroid excretion in CAH, including their effects on 226	
alternative pathway androgen synthesis, namely the alternative “backdoor” pathway to DHT and the 11-227	
oxygenated C19 steroid pathway. 228	
Eleements of the alternative “backdoor” pathway to DHT were first described by Wilson, Auchus 229	
and colleagues, reporting the synthesis of 5a-androstanediol from 17OHP, with 3α,5α-17HP as the 230	
intermediate in the fetal testis of the tammar wallaby pouch young (5). They hypothesized that this pathway 231	
could extend to the conversion of 5a-androstanediol to 5a-dihdyrotestosterone (DHT), thereby achieving 232	
active androgen synthesis without the classic pathway intermediates DHEA, androstenedione and 233	
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testosterone. This led Auchus to coin the term “backdoor pathway” for this alternative pathway to DHT 234	
synthesis (3). They later showed that the final step to DHT can indeed take place in the gonads of the 235	
brushtail possum, the tammar wallaby, and the short tail opossum (16-18). Arlt and colleagues were the 236	
first to suggest the relevance of the alternative pathway to DHT in humans, as an explanation for the 237	
virilization of newborn girls affected by CAH, utilizing the example of CAH due to P450 oxidoreductase 238	
deficiency, which results in disruption of the classic androgen pathway (4). Though that work focused on 239	
the role of the alternative pathway in prenatal life, they postulated that synthesis of DHT via the alternative 240	
pathway is likely to occur or increase, respectively, if there is an increase in either the availability of its 241	
substrate 17OHP or the activity of 5a-reductase type 1 activity, which catalyzes the first step of the 242	
alternative pathway. Both progesterone and 17OHP are efficient substrates for the 5α-reductase activity of 243	
SRD5A1 (19) and both these steroids accumulate in CAH with impaired 21-hydroxylase activity. Ogata’s 244	
group showed increased urinary excretion of the alternative pathway intermediate 3a,5a-17HP in patients 245	
with CAH due to P450 oxidoreductase deficiency (20); P450 oxidoreductase serves as the electron donor 246	
enzyme to 21-hydroxylase and therefore its disruption results in impaired 21-hydroxylase activity. 247	
Subsequently, Kamrath et al. demonstrated increased 3a,5a-17HP in newly diagnosed and hence untreated 248	
patients with CAH due to 21OHD aged 1 day to 25 years, noting the highest excretion amounts in the 249	
neonatal period (6). In this study investigating the steroid metabolome in adult CAH patients on established 250	
GC therapy, we found that while classic androgen pathway activity was significantly reduced, there was 251	
significantly increased excretion of 3a,5a-17HP, indicating an increased relative contribution of alternative 252	
androgen pathway DHT synthesis to androgen excess in CAH also in adulthood and in patients receiving 253	
regular GC treatment.  254	
We also found increased excretion of 11b-OH-An, the major metabolite of 11-oxygenated 19-255	
carbon androgens. Of note, Kamrath et al. also showed significantly increased excretion of 11b-OH-An in 256	
untreated CAH patients. However, at the time, they considered 11b-OH-An a classic pathway metabolite, 257	
while in fact this steroid represents the major metabolite of 11β-hydroxy-androstenedione and other 11-258	
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oxygenated 19-carbon androgens (15), effectively the second alternative pathway to the synthesis of active 259	
androgens. Its end products, 11-keto-testosterone and 11-keto-DHT, which have shown similar androgenic 260	
activity to testosterone and DHT (7-10). In a very recent publication, serum metabolome profiling by 261	
tandem mass spectrometry demonstrated 3-4 fold increased circulating concentrations of 11b-hydroxy-262	
androstenedione, 11-keto-androstenedione, 11b-hydroxy-testosterone, and 11-keto-testosterone in patients 263	
with 21OHD (21). However, this was done in a cross-sectional cohort of CAH patients with no detailed 264	
data on GC therapy available. 265	
In our study, conventional GC therapy appeared to control the activity of the alternative androgen 266	
synthesis pathways less efficiently than classic pathway synthesis. The latter we even found to be 267	
significantly suppressed in CAH patients, below the levels observed in healthy sex- and age-matched 268	
controls, indicative of relative GC over-treatment that is frequently observed in adult patients with CAH 269	
(22). Studying the diurnal variation of steroid excretion in our patients, we observed that the increased 270	
excretion of the alternative pathway metabolites 3a,5a-17HP and 11b-OH-An is most likely consequent to 271	
the early morning surge in ACTH, which is unopposed in CAH patients on conventional GC therapy. 272	
By contrast, we found that Chronocort, a modified release hydrocortisone preparation, exerted 273	
much improved control of alternative pathway-mediated androgen excess. Chronocort has been shown to 274	
yield cortisol delivery mimicking physiological cortisol secretion (13), resulting in significant 275	
normalization of circulating 17OHP and androstenedione levels in a previously published phase 2 study in 276	
CAH patients (14). This effect was almost more impressively visible when studying the urines of this cohort 277	
of 16 patients in our study, with close to normalization of 17OHP metabolite excretion in Chronocort-278	
treated patients. Conventional GC treatment never normalizes 17OHP secretion and if present, this would 279	
be considered an indicator of significant over-replacement. However, near normal diurnal provision of 280	
cortisol by Chronocort exerted superior control of 17OHP secretion and thereby also of both alternative 281	
androgen pathways driving androgen excess in CAH, which are both fed by the conversion of 17OHP, 282	
either to 11-oxygenated 19-carbons steroids or to 3a,5a-17HP and further downstream to DHT via the 283	
13	
	
“backdoor pathway”. An alternative modified release formulation of hydrocortisone, Plenadren, has 284	
immediate and delayed release actions but is licensed for use in adrenal insufficiency, where it is taken first 285	
thing the morning as a once daily medication, (23)  and was not studied here. In the only paper to report 286	
use of Plenadren in CAH, six patients with CAH were included in an open label trial of Plenadren where 287	
BMI, HbA1c and quality of life were measured but androgens were not reported.(24) 288	
Importantly, in our study, the analysis of the exclusive cortisol metabolites 11β-hydroxy-289	
etiocholanolone and 11-oxo-etiocholanolone (15) clearly indicated a higher excretion in the patients on 290	
conventional hydrocortisone treatment than in those treated with Chronocort, the modified release 291	
hydrocortisone preparation. This means that the absolute amount of bioavailable cortisol was actually lower 292	
in Chronocort-treated CAH patients, supporting the assumption that it was not the total amount of 293	
glucocorticoid but the improved diurnal delivery of cortisol by Chronocort, and therefore the better control 294	
of the early morning ACTH and steroid surge, that results in the superior control of excess 17OHP and 295	
androgen production. 296	
A limitation of our study was the fact the CAH patient groups receiving the three conventional GC 297	
preparations, hydrocortisone, prednisolone and dexamethasone, were not matched for biochemical control 298	
at baseline and were studied cross-sectionally and not during a controlled cross-over study. However, they 299	
were a cohort of considerable size recruited from two large specialist centers, which ensures a relative 300	
homogenization of clinical presentation. An advantage of our study was the inclusion of adult patients only, 301	
which allowed us to dissect androgen production in detail. 302	
In conclusion, we have identified significant alternative androgen synthesis pathway activity in 303	
adult patients with CAH on conventional GC therapy that persists despite suppression of classic pathway 304	
androgen production by relative glucocorticoid overtreatment. However, we found that the modified release 305	
hydrocortisone preparation Chronocort results in superior control of alternative pathway androgen 306	
production, most likely by reducing the early morning surge in excess 17OHP, which in CAH represents 307	
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Fig. 1: Schematic overview of steroidogenesis. The graph depicts steroidogenesis including the classic 398	
androgen synthesis pathway (shaded in dark grey) and the two alternative androgen synthesis pathways 399	
(shaded in light grey; top, 11-oxygenated 19-carbon steroids; bottom, alternative pathway to DHT). 3α,5α-400	
17HP is labelled by its alternative full name, 17-OH-allopregnanolone. 401	
 402	
Fig. 2: 24-h urinary steroid excretion in 55 CAH patients and 60 healthy sex- and age-matched 403	
controls. For explanation of steroid metabolite abbreviations see Table 1. Data are shown as µg/24 hours 404	





percentiles (whiskers). Urinary excretion of 3α5α-17HP available for 38 of the total CAH cohort. Analyses 406	
were undertaken using the Mann-Whitney test. * p≤0.05, *** p≤0.001 for CAH vs. controls.  407	
 408	
Fig. 3: 8-hourly diurnal urinary steroid metabolite excretion in 16 subjects with CAH due to 21OHD 409	
and 12 healthy controls. Data are shown for night (23:00-07:00; dark grey), morning (07:00-15:00; white) 410	
and evening (15:00-23:00; light grey) time periods. Excretion of the major androgen metabolites An+Et is 411	
shown for male subjects with CAH (n=8) and matched healthy controls (n=12). Box-and-whisker plots 412	




 percentiles (whiskers). Comparisons were 413	
drawn within CAH and control groups with analyses undertaken using the Friedman test, which was applied 414	
to the CAH subjects and the control subjects separately. * p≤0.05 for comparison of steroid excretion during 415	
different 8-h periods. 416	
 417	
Fig. 4: Effect of Chronocort treatment on 24-hour urinary steroid metabolite excretion in subjects 418	
with CAH due to 21OHD. Results are shown for subjects with CAH at baseline on conventional GC 419	
therapy prior to commencing Chronocort (BL; n=16), at day 4 of Chronocort treatment (D4; n=16) and 420	
after six months of Chronocort treatment (M6; n=15). Box-and-whisker plots represent median, 421	
20	
	




 percentiles (whiskers). Analyses were undertaken using repeated 422	
Wilcoxon tests with Bonferroni correction to compare between matched CAH subjects. * p≤0.05. 423	
 424	
Fig. 5: Urinary steroid excretion in 60 healthy controls and CAH patients treated with Chronocort 425	
(n=16), conventional immediate release hydrocortisone (n=13), prednisolone (n=27) or 426	
dexamethasone (n=15). Urinary excretion of 3α5α-17HP available for 54 of the total CAH cohort; 16 on 427	
Chronocort, 11 on conventional hydrocortisone, 21 on prednisolone and 6 on dexamethasone. 428	
Glucocorticoid treatment was stable for at least six months at the time of 24-h urine collection. Box-and-429	




 percentiles (whiskers). Analyses 430	




Table 1:  Demographic data for participants with CAH managed with either conventional glucocorticoid 433	
(GC) treatment or Chronocort and healthy matched control subjects. Data for age are shown as median 434	
(range). For Chronocort-treated patients their conventional GC medication prior to commencing 435	
Chronocort therapy is shown.  436	















N=55 N=60 N=16 n=12 
Sex Male : Female n:n 28 : 27 32 : 28 8 : 8 12 : 0 




Salt-wasting (%) 41 (74.5)
 
- 12 (75) - 
 Simple virilizing (%) 14 (25.5) - 4 (25) - 
Glucocorticoid 
preparation 
Hydrocortisone n (%) 13 (24) - 3 (19) - 
Prednisolone n (%) 27 (49) - 8 (50)* - 
 Dexamethasone n (%) 15 (27) - 5 (31) - 
 437	
* One patient received a combined hydrocortisone and prednisolone preparation prior to commencing 438	
Chronocort therapy and has been included in the prednisolone group439	
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Fig. 3: 8-hourly diurnal urinary steroid metabolite excretion in 16 subjects with CAH due to 21OHD 





Fig. 4: Effect of Chronocort treatment on 24-hour urinary steroid metabolite excretion in 





Fig. 5: Urinary steroid excretion in 60 healthy controls and CAH patients treated with Chronocort 
(n=16), conventional immediate release hydrocortisone (n=13), prednisolone (n=27) or 
dexamethasone (n=15). 
 
 
 
 
	
